Nephros (Nephros) EBIT : $-1.44 Mil (TTM As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Nephros EBIT?

Nephros's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-0.17 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.44 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nephros's annualized ROC % for the quarter that ended in Mar. 2024 was -13.18%. Nephros's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -14.64%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nephros's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -6.75%.

Nephros EBIT Historical Data

The historical data trend for Nephros's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nephros EBIT Chart

Nephros Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-3.21

-4.42

-2.74

-4.26

-1.57

Nephros Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-0.31	-0.43	-0.18	-0.65	-0.17

Competitive Comparison of Nephros's EBIT

For the Medical Instruments & Supplies subindustry, Nephros's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nephros's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nephros's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nephros's EV-to-EBIT falls into.

Nephros EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.44 Mil.

Nephros (NAS:NEPH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nephros's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-0.8 * ( 1 - 0% )	/	( (5.887	+	6.256)	/ 2 )
=	-0.8	/	6.0715
=	-13.18 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.861	-	1.667	-	( 4.307	-	max(0, 2.113	-	8.405	+	4.307	))
=	5.887

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.416	-	1.527	-	( 3.633	-	max(0, 1.929	-	8.13	+	3.633	))
=	6.256

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Nephros's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.672	/	( ( (1.959 + max(2.431, 0))	+	(1.822 + max(2.97, 0)) )	/	2 )
=	-0.672	/	( ( 4.39	+	4.792 )	/	2 )
=	-0.672	/	4.591
=	-14.64 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.496	+	2.47	+	0.132)	-	(1.667	+	0	+	0)
=	2.431

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.518	+	2.779	+	0.2)	-	(1.527	+	0	+	2.2204460492503E-16)
=	2.97

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nephros's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-1.436	/	21.273
	=	-6.75 %

Nephros EBIT Related Terms

Thank you for viewing the detailed overview of Nephros's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Nephros (Nephros) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nephros Inc (NAS:NEPH) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

NPJP:Germany

Address

380 Lackawanna Place, South Orange, NJ, USA, 07079

Website

https://www.nephros.com

Nephros Inc is a commercial-stage company that develops and sells high performance water solutions to the medical and commercial markets. In medical markets, it sell water filtration products and waterborne pathogen detection products. In commercial markets, the company manufacture and sell water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The operating segments of the group are Water Filtration, Pathogen Detection and Renal Products of which key revenue is derived from Water Filtration segment.

Executives

Banks Robert R. Jr.	director, officer: President and CEO	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Judy Krandel	officer: Chief Financial Officer	320 W. 37TH STREET, 13TH FLOOR, NEW YORK NY 10018
Joseph Michael Harris	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Wesley S. Lobo	officer: Chief Marketing Officer	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Tom Gwydir	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Andrew Astor	officer: Chief Financial Officer	380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Charles E Davidson	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp	director, 10 percent owner	777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Gp Llc	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401
Oliver J. Spandow	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daniel S. D'agostino	officer: Chief Financial Officer	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daron Evans	director, officer: President and CEO	C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Alisa Lask	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Paul A Mieyal	director	C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830